Product Description: Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids[1][2].
Applications: Cancer-programmed cell death
Formula: C85H115N18F3O25S2
Citations: Cell Mol Life Sci. 2022 Sep 19;79(10):523./Stem Cell Res Ther. 2023 Oct 26;14(1):305./Cell Prolif. 2023 Mar 27;e13460.
References: [1]Nile AH, et, al. A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells. Nat Chem Biol. 2018 Jun;14(6):582-590./[2]Larasati Y, et, al. Unlocking the Wnt pathway: Therapeutic potential of selective targeting FZD7 in cancer. Drug Discov Today. 2022 Mar;27(3):777-792.
Molecular Weight: 1910.07
Compound Purity: 99.35
Research Area: Cancer
Solubility: DMSO : 33.33 mg/mL (ultrasonic)/H2O : < 0.1 mg/mL
Target: Wnt